Highlights Newsletter 2
This newsletter presents you the following key sessions:
1. Atezolizumab fails to meet PFS endpoint in advanced squamous cell carcinoma of the penis
3. Lenvatinib fails to improve on pembrolizumab in patients with advanced urothelial carcinoma
5. Novel predictive biomarkers of response to immune checkpoint blockade in the TITAN-RCC trial